title: [Reduction of in-hospital mortality and improved secondary prevention after acute myocardial infarction. First results from the registry of secondary prevention after acute myocardial infarction (SAMI)].
abstract: OBJECTIVE
  In hospital mortality of acute myocardial infarction (AMI) has been reduced due to the availability of better therapeutic strategies. But there is still a gap between mortality rates in randomised trials and daily clinical practice. Thus, it was aim of the present registry to document the course and outcome of patients with AMI and to improve patient care by implementing recent guidelines.
  
  
  METHODS
  In a nationwide registry study in hospitals in Germany with a cardiology unit or an internal medicine department data on consecutive patients were recorded for six to twelve months at admission, discharge and during a follow-up of one year.
  
  
  RESULTS
  From 02/2003 until 10/2004 a total of 5,353 patients with acute myocardial infarction (65.7 % male, mean age of 67.6 +/- 17.7 years; 55.1 % of them with ST elevation myocardial infarction (STEMI) were included in the registry. Of the patients with STEMI, 76.6 % underwent acute intervention, 37.1 % had thrombolysis, 69.7 % percutaneous transluminal coronary angioplasty (PTCA). 40.0 % of those with non-Stemi (NSTEMI) had an acute intervention, 6.6 % thrombolysis, 73.5 % PTCA. Recommended secondary prevention consisted of ASS (93.2 %), beta-blockers (93.0 %), CSE-inhibitors (83.5 %), ACE-inhibitors (80.9 %) and clopidogrel (74.0 %). In-hospital mortality was 10.5 % (STEMI) and 7.4 % (NSTEMI).
  
  
  CONCLUSIONS
  The 9 % mortality among patients with acute myocardial infarction treated in the hospitals participating in the SAMI registry is low compared to that in similar collectives. The high number of patients who had thrombofibrinolysis and coronary interventions as well as the early initiation of drug therapy contributed to these results. Medical treatment in the prehospital phase of these patients remains still insufficient and to a substantial extent contributes to the mortality of acute myocardial infarction.
authors.affiliation: Klinikum Lippe GmbH, Fachbereich Herz-Kreislauf, Detmold, Germany. ulrich.tebbe@klinikum-lippe.de
authors.forename: U
authors.initials: U
authors.lastname: Tebbe
authors.forename: C
authors.initials: C
authors.lastname: Messer
authors.forename: E
authors.initials: E
authors.lastname: Stammwitz
authors.forename: G S
authors.initials: GS
authors.lastname: The
authors.forename: J
authors.initials: J
authors.lastname: Dietl
authors.forename: K-O
authors.initials: KO
authors.lastname: Bischoff
authors.forename: U
authors.initials: U
authors.lastname: Schulten-Baumer
authors.forename: J
authors.initials: J
authors.lastname: Tebbenjohanns
authors.forename: H
authors.initials: H
authors.lastname: Gohlke
authors.forename: P
authors.initials: P
authors.lastname: Bramlage
mesh_terms: D000368:Aged; D003266:Continuity of Patient Care / Q000592:standards; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005858:Germany; D017052:Hospital Mortality / Q000639:trends; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000401:mortality* / Q000517:prevention & control* / Q000628:therapy; D015425:Myocardial Reperfusion / Q000379:methods; D005791:Patient Care / Q000592:standards*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D011446:Prospective Studies; D011787:Quality of Health Care; D012042:Registries; D013997:Time Factors
chemical_list: D005343:Fibrinolytic Agents